X
[{"orgOrder":0,"company":"AM-Pharma","sponsor":"Cowen Healthcare Investments","pharmaFlowCategory":"D","amount":"$176.0 million","upfrontCash":"Undisclosed","newsHeadline":"AM-Pharma Increases Funding To \u20ac163m For Phase-Iii Trial Of Recap In Sa-Aki","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"AM-Pharma"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Initiates Phase 2 Trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"AM-Pharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
recAP (Ilofotase Alfa) is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase. It is under phase 2 clinical development for the treatment of cardiac surgery-associated renal damage.
Lead Product(s):
Ilofotase Alfa
Therapeutic Area: Nephrology
Product Name: recAP
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 16, 2024
Details:
New capital to be used to support a multi-national pivotal Phase III trial of recAP in 1,400 patients with sepsis-associated-acute kidney injury (SA-AKI).
Lead Product(s):
Ilofotase alfa
Therapeutic Area: Nephrology
Product Name: recAP
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Cowen Healthcare Investments
Deal Size: $176.0 million
Upfront Cash: Undisclosed
Deal Type: Funding
March 31, 2020